TITLE

HADASSAH/HARVARD MEDICAL BEGIN PHASE 1 AUTOIMMUNE THERAPY

PUB. DATE
March 2008
SOURCE
Worldwide Biotech;Mar2008, Vol. 20 Issue 3, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article announces a partnership reached among Hadasit, Harvard Medical School (HMS), and Brigham and Women's Hospital (BWH) to develop a new orally administered therapeutic option for autoimmune diseases. Comments from Professor Shlomo Mor-Yosef, director general of Hadassah Medical Organization, are included. Particular focus is given to the combination therapy. It also presents information on results of pre-clinical studies and the etiology of autoimmune diseases.
ACCESSION #
30001582

 

Related Articles

  • Out, but not down Sorting out the Hadassah resignation. BERKMAN, JACOB // New Jersey Jewish News;1/14/2010, Vol. 64 Issue 2, p24 

    The article focuses on the confusion on the resignation of director general of the Hadassah Medical Organization in Jerusalem Shlomo Mor-Yosef, which was reported that he is leaving because has been unhappy in his post for years.

  • Asan Medical Center and Harvard Medical International.  // Journal of Alternative & Complementary Medicine;Dec2001 Supplement 1, Vol. 7 Issue 6, p2 

    Focuses on the alliance of Asan Medical Center of Seoul, South Korea and Harvard Medical International of Harvard University School of Medicine. Background of the establishment of the medical institutions.

  • The Other Crippling Joint Disease. Bjerklie, David // Time;12/9/2002, Vol. 160 Issue 24, p72 

    Discusses rheumatoid arthritis (RA) and how it differs from osteoarthritis. Idea that RA is a systemic disease, an autoimmune disorder in which one's defense system attacks the joints by way of the thin layer of cells called the synovium that line and lubricate the joints; Symptoms of swollen...

  • Pure red cell aplasia associated with type I autoimmune polyglandular syndrome--successful response to treatment with mycophenolate mofetil: case report and review of literature. Bakrac, Milena; Jurisic, Vladimir; Kostic, Tanja; Popovic, Vera; Pekic, Sandra; Kraguljac, Nada; Colovic, Milica // Journal of Clinical Pathology;Jun2007, Vol. 60 Issue 6, p717 

    The article describes the case of a 33-year old woman who had pure red cell aplasia (PRCA) that is associated with type 1 autoimmune polyglandular syndrome. PRCA is a hematological condition that is characterized by anemia, reticulocytopenia and erythroid hypoplasia. After the patient was...

  • Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia. S MacCallum // Journal of Clinical Pathology;May2009, Vol. 62 Issue 5, p468 

    Autoimmune haemolysis or thrombocytopenia can complicate purine nucleoside monotherapy for chronic lymphocytic leukaemia (CLL), but Evans syndrome is rare. This is a report of the occurrence of pancytopenia secondary to a unique combination of red cell aplasia with autoimmune thrombocytopenia...

  • Symposium introduction: metabolic syndrome and the onset of cancer.  // American Journal of Clinical Nutrition;Sep2007, Vol. 86 Issue 3, p817S 

    The article discusses the Metabolic Syndrome and the Onset of Cancer hosted by the Harvard Medical School Division of Nutrition that was held in Boston, Massachusetts from March 15-16, 2006. Topics discussed include the etiologic role of metabolic syndrome in cancer, the epidemiologic studies on...

  • Clinical and Laboratory Examinations in the Subgroups of Chronic Urticaria. Irinyi, Beatrix; Széles, György; Gyimesi, Edit; Tumpek, Judit; Herédi, Emese; Dimitrios, Georgitsis; Ádány, Róza; Hunyadi, János; Szegedi, Andrea // International Archives of Allergy & Immunology;2007, Vol. 144 Issue 3, p217 

    Background: The aetiology of chronic urticaria is heterogeneous. Physical urticaria (PU) is estimated at around 35%, autoimmune urticaria (AIU) at 25% and chronic idiopathic urticaria (CIU) at 35% of all chronic urticaria cases. Methods: Differences in clinical and laboratory parameters among...

  • Nationwide survey on current treatments for IgA nephropathy in Japan. Matsuzaki, Keiichi; Suzuki, Yusuke; Nakata, Junichiro; Sakamoto, Naoko; Horikoshi, Satoshi; Kawamura, Tetsuya; Matsuo, Seiichi; Tomino, Yasuhiko // Clinical & Experimental Nephrology;Dec2013, Vol. 17 Issue 6, p827 

    Background: A wide variety of treatments, including tonsillectomy and steroid pulse therapy (TSP), are performed for the various stages of IgA nephropathy (IgAN) in Japan. However, the current status of treatments for IgAN patients in Japan is still unclear. The objective of the present study...

  • United States : AstraZeneca and Kyowa Hakko Kirin partner on immuno-oncology clinical study.  // TendersInfo News;7/31/2014, p1 

    The article reports that pharmaceutical firm AstraZeneca has entered into a partnership with biotechnology firm Kyowa Hakko Kirin for conducting a immuno-oncology study, and presents the views of Briggs Morrison, chief medical officer (CMO) at AstraZeneca, on the combination therapy of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics